HomeCONGRESS

CONGRESS

View Category
Day 3

AQUARIUS: Aliskiren, without impact on the progression of atherosclerosis

This double-blind, multicenter randomized study compared aliskiren versus placebo in 613 patients with coronary artery disease and...
solaci -
Learn More
Day 3

BIC 8: Copetin associated with troponin can rule out acute myocardial infarction in the emergency room.

The acute chest pain is responsible for more than 11 % of queries to an emergency service...
solaci -
Learn More
Day 3

Group Tour of France: good news for cyclists.

The benefits of regular physical activity are well established, but there are some controversies related to the...
solaci -
Learn More
Day 2

SAVOR-TIMI 53: Saxagliptin showed no cardiovascular benefit

The cardiovascular safety and efficacy of some hypoglycemic including saxagliptin (Onglyza), an inhibitor of dipeptidyl peptidase 4...
solaci -
Learn More
Day 2

ASSURE: Inducing Apo A-1 agent failed to reduce atherosclerotic plaque

Induction apoA-1  synthesis is a new therapeutic approach for the functional HDL particles generation. The RVX-208 induces...
solaci -
Learn More
Day 2

COMPARE: Losartan shows promising results in patients with Marfan syndrome

Patients with Marfan syndrome (connective tissue disorder) are more susceptible to aortic dilation and consequently dissection and...
solaci -
Learn More
Day 2

EXAMINE: The alogliptin is safe for treating type 2 diabetes in patients with a recent history of acute coronary syndrome.

Type 2 diabetes is associated both microvascular and macrovascular disease. Adequate glycemic control can reduce the risk...
solaci -
Learn More
EuroPCR 2015.

EuroPCR 2015.

Find the coverage of the Congress- May 19 - 22 at the Palais des Congrès in Paris,...
solaci -
Learn More